{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:58:08Z","timestamp":1793750288852,"version":"4.6.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64829-6","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:16:15Z","timestamp":1768277775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intranasal replicon vaccine establishes mucosal immunity and protects against H5N1 and H7N9 influenza"],"prefix":"10.1038","volume":"17","author":[{"given":"Matthew R.","family":"Ykema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshan N.","family":"Kasal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine F.","family":"Jennewein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0001-8787","authenticated-orcid":false,"given":"Ethan","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Beaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-8966","authenticated-orcid":false,"given":"Eduard","family":"Melief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin S.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3210-4747","authenticated-orcid":false,"given":"Wynton D.","family":"McClary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raodoh","family":"Mohamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Casper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airn Tolnay","family":"Hartwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-4063","authenticated-orcid":false,"given":"Emily A.","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"64829_CR1","unstructured":"CDC. About Estimated Flu Burden. https:\/\/www.cdc.gov\/flu-burden\/php\/about\/index.html (2024)."},{"key":"64829_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J. Infect. Dis. 218, 347\u2013354 (2018).","journal-title":"J. Infect. Dis."},{"key":"64829_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3201\/eid3007.240508","volume":"30","author":"ER Burrough","year":"2024","unstructured":"Burrough, E. R. et al. Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024. Emerg. Infect. Dis. 30, 1335\u20131343 (2024).","journal-title":"Emerg. Infect. Dis."},{"key":"64829_CR4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/v15040980","volume":"15","author":"EM Abdelwhab","year":"2023","unstructured":"Abdelwhab, E. M. & Mettenleiter, T. C. Zoonotic animal influenza virus and potential mixing vessel hosts. Viruses 15, 980 (2023).","journal-title":"Viruses"},{"key":"64829_CR5","unstructured":"CDC. USDA reported H5N1 bird flu detections in US backyard and commercial poultry. Avian Influenza (Bird Flu) https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/data-map-commercial.html (2024)."},{"key":"64829_CR6","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07766-6","volume":"633","author":"AJ Eisfeld","year":"2024","unstructured":"Eisfeld, A. J. et al. Pathogenicity and transmissibility of bovine H5N1 influenza virus. Nature 633, 426\u2013432 (2024).","journal-title":"Nature"},{"key":"64829_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1056\/NEJMra0707279","volume":"358","author":"Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza, A. V.","year":"2008","unstructured":"Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza, A. V. et al. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358, 261\u2013273 (2008).","journal-title":"N. Engl. J. Med."},{"key":"64829_CR8","unstructured":"CDC. H5 bird flu: current situation. Avian Influenza (Bird Flu) https:\/\/www.cdc.gov\/bird-flu\/situation-summary\/index.html (2025)."},{"key":"64829_CR9","unstructured":"LDH reports first U.S. H5N1-related human death | La Dept. of Health. https:\/\/ldh.la.gov\/news\/H5N1-death."},{"key":"64829_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/cid\/ciz779","volume":"71","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Factors associated with fatality due to avian influenza A(H7N9) infection in China. Clin. Infect. Dis. 71, 128\u2013132 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"64829_CR11","unstructured":"de La Hamaide, S. US Reports First Outbreak of Deadly H7N9 Bird Flu Since 2017 (Reuters, 2025)."},{"key":"64829_CR12","unstructured":"Schnirring, L. H7N9 Avian Flu Strikes Mississippi Broiler Farm https:\/\/www.cidrap.umn.edu\/avian-influenza-bird-flu\/h7n9-avian-flu-strikes-mississippi-broiler-farm (CIDRAP Center for Infectious Disease Research & Policy Research and Innovation Office, University of Minnesota, Minneapolis, 2025)."},{"key":"64829_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1128\/CMR.00039-14","volume":"28","author":"JL Sanchez","year":"2015","unstructured":"Sanchez, J. L. et al. Respiratory infections in the U.S. military: recent experience and control. Clin. Microbiol. Rev. 28, 743\u2013800 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"64829_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nature12392","volume":"501","author":"T Watanabe","year":"2013","unstructured":"Watanabe, T. et al. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501, 551\u2013555 (2013).","journal-title":"Nature"},{"key":"64829_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7553","volume":"6","author":"H Zaraket","year":"2015","unstructured":"Zaraket, H. et al. Mammalian adaptation of influenza A(H7N9) virus is limited by a narrow genetic bottleneck. Nat. Commun. 6, 6553 (2015).","journal-title":"Nat. Commun."},{"key":"64829_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nature12372","volume":"499","author":"X Xiong","year":"2013","unstructured":"Xiong, X. et al. Receptor binding by an H7N9 influenza virus from humans. Nature 499, 496\u2013499 (2013).","journal-title":"Nature"},{"key":"64829_CR17","unstructured":"FDA. Vaccines licensed for use in the United States. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states (2024)."},{"key":"64829_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167\u2013182 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64829_CR19","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1016\/j.vaccine.2023.10.072","volume":"42","author":"ID Plumb","year":"2024","unstructured":"Plumb, I. D. et al. Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022\u2013May 2023. Vaccine 42, 2543\u20132552 (2024).","journal-title":"Vaccine"},{"key":"64829_CR20","doi-asserted-by":"publisher","unstructured":"Kreier, F. Combined COVID\u2013flu vaccines are coming: Moderna jab clears major test. Nature https:\/\/doi.org\/10.1038\/d41586-024-02121-1 (2024).","DOI":"10.1038\/d41586-024-02121-1"},{"key":"64829_CR21","first-page":"38","volume":"34","author":"J Markarian","year":"2021","unstructured":"Markarian, J. Accelerating technology adoption to track the cold chain. BioPharm. Int. 34, 38\u201340 (2021).","journal-title":"BioPharm. Int."},{"key":"64829_CR22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1056\/NEJMc2102507","volume":"385","author":"SM Kissler","year":"2021","unstructured":"Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated persons. N. Engl. J. Med. 385, 2489\u20132491 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64829_CR23","doi-asserted-by":"publisher","first-page":"e1010802","DOI":"10.1371\/journal.ppat.1010802","volume":"18","author":"M Garcia-Knight","year":"2022","unstructured":"Garcia-Knight, M. et al. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: a longitudinal cohort study. PLoS Pathog. 18, e1010802 (2022).","journal-title":"PLoS Pathog."},{"key":"64829_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/vaccines12060670","volume":"12","author":"A Toniolo","year":"2024","unstructured":"Toniolo, A., Maccari, G. & Camussi, G. mRNA technology and mucosal immunization. Vaccines 12, 670 (2024).","journal-title":"Vaccines"},{"key":"64829_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1017\/S0033291721002609","volume":"53","author":"D Freeman","year":"2023","unstructured":"Freeman, D. et al. Injection fears and COVID-19 vaccine hesitancy. Psychol. Med. 53, 1185\u20131195 (2023).","journal-title":"Psychol. Med."},{"key":"64829_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944 (2022).","journal-title":"Lancet"},{"key":"64829_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","volume":"185","author":"S Afkhami","year":"2022","unstructured":"Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896\u2013915.e19 (2022).","journal-title":"Cell"},{"key":"64829_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41590-018-0260-6","volume":"20","author":"SR Allie","year":"2019","unstructured":"Allie, S. R. et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol. 20, 97\u2013108 (2019).","journal-title":"Nat. Immunol."},{"key":"64829_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e13 (2020).","journal-title":"Cell"},{"key":"64829_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103037","volume":"24","author":"X An","year":"2021","unstructured":"An, X. et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience 24, 103037 (2021).","journal-title":"iScience"},{"key":"64829_CR31","volume":"3","author":"XF Li","year":"2022","unstructured":"Li, X. F. et al. A highly immunogenic live-attenuated vaccine candidate prevents SARS-CoV-2 infection and transmission in hamsters. Innovation 3, 100221 (2022).","journal-title":"Innovation"},{"key":"64829_CR32","doi-asserted-by":"publisher","first-page":"2045853","DOI":"10.1080\/21645515.2022.2045853","volume":"18","author":"K Dhama","year":"2022","unstructured":"Dhama, K. et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum. Vaccin. Immunother. 18, 2045853 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"64829_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","volume":"25","author":"A Gerhardt","year":"2022","unstructured":"Gerhardt, A. et al. A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Mol. Ther. Methods Clin. Dev. 25, 205\u2013214 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"64829_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-021-00424-2","volume":"7","author":"EA Voigt","year":"2022","unstructured":"Voigt, E. A. et al. A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. npj Vaccines 7, 1\u201313 (2022).","journal-title":"npj Vaccines"},{"key":"64829_CR35","doi-asserted-by":"crossref","unstructured":"Jennewein, M. F. et al. Intranasal replicon SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission. Mol. Ther. 33, 3286\u20133306 (2025).","DOI":"10.1016\/j.ymthe.2025.04.007"},{"key":"64829_CR36","doi-asserted-by":"crossref","unstructured":"McClary, W. D. et al. An intranasally- and intramuscularly-deliverable nanostructured lipid carrier-replicon RNA vaccine drives protective systemic and mucosal immunity. J. Control. Release. 385, 114054 (2025).","DOI":"10.1016\/j.jconrel.2025.114054"},{"key":"64829_CR37","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1056\/NEJMoa073121","volume":"358","author":"HJ Ehrlich","year":"2008","unstructured":"Ehrlich, H. J. et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358, 2573\u20132584 (2008).","journal-title":"N. Engl. J. Med."},{"key":"64829_CR38","doi-asserted-by":"publisher","first-page":"L833","DOI":"10.1152\/ajplung.00173.2001","volume":"282","author":"DS Southam","year":"2002","unstructured":"Southam, D. S., Dolovich, M., O\u2019Byrne, P. M. & Inman, M. D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L833\u2013L839 (2002).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"64829_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00420-6","volume":"6","author":"S Chivukula","year":"2021","unstructured":"Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. npj Vaccines 6, 1\u201315 (2021).","journal-title":"npj Vaccines"},{"key":"64829_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-024-00980-3","volume":"9","author":"T Hauguel","year":"2024","unstructured":"Hauguel, T. et al. Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines. npj Vaccines 9, 1\u201313 (2024).","journal-title":"npj Vaccines"},{"key":"64829_CR41","doi-asserted-by":"publisher","first-page":"e00414","DOI":"10.1128\/CVI.00414-16","volume":"24","author":"DF Hoft","year":"2017","unstructured":"Hoft, D. F. et al. Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults. Clin. Vaccin. Immunol. 24, e00414\u2013e00416 (2017).","journal-title":"Clin. Vaccin. Immunol."},{"key":"64829_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.hlife.2023.12.005","volume":"2","author":"Y Lin","year":"2024","unstructured":"Lin, Y., Hu, Z., Fu, Y.-X. & Peng, H. Mucosal vaccine development for respiratory viral infections. hLife 2, 50\u201363 (2024).","journal-title":"hLife"},{"key":"64829_CR43","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","volume":"71","author":"NJ Carter","year":"2011","unstructured":"Carter, N. J. & Curran, M. P. Live attenuated influenza vaccine (FluMist\u00ae; FluenzTM). Drugs 71, 1591\u20131622 (2011).","journal-title":"Drugs"},{"key":"64829_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijid.2014.05.016","volume":"27","author":"J Li","year":"2014","unstructured":"Li, J., Ar\u00e9valo, M. T., Chen, Y., Chen, S. & Zeng, M. T-cell-mediated cross-strain protective immunity elicited by prime\u2013boost vaccination with a live attenuated influenza vaccine. Int. J. Infect. Dis. 27, 37\u201343 (2014).","journal-title":"Int. J. Infect. Dis."},{"key":"64829_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05482-0","volume":"9","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun. 9, 3361 (2018).","journal-title":"Nat. Commun."},{"key":"64829_CR46","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","volume":"25","author":"K Bahl","year":"2017","unstructured":"Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316\u20131327 (2017).","journal-title":"Mol. Ther."},{"key":"64829_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-023-00752-5","volume":"8","author":"CM Kackos","year":"2023","unstructured":"Kackos, C. M. et al. Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection. npj Vaccines 8, 1\u201311 (2023).","journal-title":"npj Vaccines"},{"key":"64829_CR48","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","volume":"26","author":"JH Erasmus","year":"2018","unstructured":"Erasmus, J. H. et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol. Ther. 26, 2507\u20132522 (2018).","journal-title":"Mol. Ther."},{"key":"64829_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep44727","volume":"7","author":"S-S Wong","year":"2017","unstructured":"Wong, S.-S. et al. The immune correlates of protection for an avian influenza H5N1 vaccine in the ferret model using oil-in-water adjuvants. Sci. Rep. 7, 44727 (2017).","journal-title":"Sci. Rep."},{"key":"64829_CR50","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"64829_CR51","doi-asserted-by":"publisher","first-page":"121180","DOI":"10.1016\/j.ijpharm.2021.121180","volume":"609","author":"H Xu","year":"2021","unstructured":"Xu, H., Cai, L., Hufnagel, S. & Cui, Z. Intranasal vaccine: factors to consider in research and development. Int. J. Pharm. 609, 121180 (2021).","journal-title":"Int. J. Pharm."},{"key":"64829_CR52","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-virology-010320-044746","volume":"7","author":"S Gouma","year":"2020","unstructured":"Gouma, S., Anderson, E. M. & Hensley, S. E. Challenges of making effective influenza vaccines. Annu. Rev. Virol. 7, 495\u2013512 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"64829_CR53","doi-asserted-by":"publisher","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","volume":"9","author":"DM Skowronski","year":"2014","unstructured":"Skowronski, D. M. et al. Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE 9, e92153 (2014).","journal-title":"PLoS ONE"},{"key":"64829_CR54","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","volume":"27","author":"G Maruggi","year":"2019","unstructured":"Maruggi, G., Zhang, C., Li, J., Ulmer, J. B. & Yu, D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757\u2013772 (2019).","journal-title":"Mol. Ther."},{"key":"64829_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100509","volume":"3","author":"S Yegorov","year":"2022","unstructured":"Yegorov, S. et al. Inactivated and live-attenuated seasonal influenza vaccines boost broadly neutralizing antibodies in children. Cell Rep. Med. 3, 100509 (2022).","journal-title":"Cell Rep. Med."},{"key":"64829_CR56","doi-asserted-by":"publisher","first-page":"987","DOI":"10.4049\/jimmunol.1002664","volume":"186","author":"K Sun","year":"2011","unstructured":"Sun, K., Ye, J., Perez, D. & Metzger, D. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J. Immunol. 186, 987\u2013993 (2011).","journal-title":"J. Immunol."},{"key":"64829_CR57","doi-asserted-by":"publisher","first-page":"13879","DOI":"10.1128\/JVI.02341-14","volume":"88","author":"IN Moore","year":"2014","unstructured":"Moore, I. N. et al. Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. J. Virol. 88, 13879\u201313891 (2014).","journal-title":"J. Virol."},{"key":"64829_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.604","volume":"10","author":"S Kar","year":"2022","unstructured":"Kar, S. et al. Oral and intranasal vaccines against SARS-CoV-2: current progress, prospects, advantages, and challenges. Immun. Inflamm. Dis. 10, e604 (2022).","journal-title":"Immun. Inflamm. Dis."},{"key":"64829_CR59","doi-asserted-by":"publisher","unstructured":"Anderer, S. FDA greenlights nasal spray flu vaccine for use at home. JAMA https:\/\/doi.org\/10.1001\/jama.2024.21299 (2024).","DOI":"10.1001\/jama.2024.21299"},{"key":"64829_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/srep46426","volume":"7","author":"N Van Hoeven","year":"2017","unstructured":"Van Hoeven, N. et al. A formulated TLR7\/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines. Sci. Rep. 7, 46426 (2017).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64829-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:56:47Z","timestamp":1768474607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64829-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64829"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64829-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. and E.A.V. declare no Competing Non-Financial Interests but the following Competing Financial Interests. A.G. and E.A.V. are co-inventors on PCT patent application PCT\/US21\/40388, \u201cCo-lyophilized RNA and Nanostructured Lipid Carrier,\u201d and related national filings, as well as US provisional patent application 63\/345,345, \u201cIntranasal Administration of Thermostable RNA Vaccines,\u201d and 63\/144,169, \u201cA thermostable, flexible RNA vaccine delivery platform for pandemic response.\u201d All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}